Cardiac Resynchronization Therapy (CRT Devices) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Device (CRT-pacemakers, CRT-defibrillators), By End-User (Hospitals, Clinics, Ambulatory Surgical Centres) Region Forecast 2019-2030

Cardiac resynchronization therapy Market size was valued at US$ 965.7 million in 2023 and is projected to reach US$ 983.4 million by 2030, registering a CAGR of 5.0% from 2024 to 2030. Cardiac Resynchronization therapy is used to treat heart diseases. Devices that are used in cardiac resynchronization therapy are known as CRT devices. Irregular heartbeats are known as arrhythmias and can be caused due to various reasons such as age, damage of the heart, genetic factors and so far used medications. CRT, or biventricular pacing, is used to improve the rhythm of the heart and reduce the symptoms that are associated with arrhythmias in heart failure patients. Heart ventricle contractions in arrhythmic patients are resynchronized by the CRT devices.

The market is the implantable devices with a microcomputer along with an enclosed battery by a tiny titanium metal case. Insulated wires known as leads are implanted along with the device so as to pass the information signals from the heart-to-heart device to carry electrical impulses to the heart. The CRT devices market is expected to show a significant growth rate during the forecast period due to the high prevalence of cardiac diseases.

As per the World Health Organisation (WHO), one of the leading causes of death worldwide is cardiovascular disease, and around 17.5 million people died from cardiovascular diseases which accounted for 31% of all global deaths in the year 2012. Cardiovascular diseases can be prevented by addressing behavioral risks like cigarette smoking, an unhealthy diet, and obesity, players in the market are focusing on R&D investments to improve product quality and minimize manufacturing costs, and also focus on the development of devices that are safe to improve compliance of the patient. For example, Medtronic and St. Jude Medical (Abbott laboratories) offer leadless pacemakers for the implantation of the equipment in the right ventricle. Moreover, increase in the usage of MRIs in clinical applications.

Key Developments

• In February 2017, RESONATE cardiac resynchronization therapy defibrillator (CRT-D) systems were launched by Boston Scientific and also received CE Mark which is available for treatment of heart failure in patients across the globe.
• In January 2017, Abbott Laboratories acquired St. Jude Medical, Inc., for future growth and to develop a diverse and strong portfolio of medical devices, nutritionals, diagnostics, and established branded generic pharmaceuticals.